Omnicell Company Leadership

OMCL Stock  USD 34.48  1.39  4.20%   
Omnicell's insiders are aggressively selling. The review of the overall insider sentiment regarding Omnicell suggests that most insiders are panicking. Omnicell employs about 3.6 K people. The company is managed by 24 executives with a total tenure of roughly 61 years. There are nearly 149.17 employees per reported executive.
Randall Lipps  Chairman
Executive Chairman, CEO and Pres
Jorge Taborga  President
Executive Vice President - Engineering
Insider Sentiment
Mostly Selling
 
Selling
 
Buying

Latest Trades

2026-03-16Corey J ManleyDisposed 7405 @ 34.69View
2026-01-08Corey J ManleyDisposed 6106 @ 49.9View
2025-09-12Corey J ManleyDisposed 3880 @ 33.25View
Insider-sentiment monitoring for Omnicell is useful because insiders may respond to operating developments before those shifts are fully reflected in market commentary. The stronger workflow is to compare insider behavior with earnings, guidance, and business changes instead of reading the transactions in isolation.

Omnicell's Workforce Through the Years

Workforce analysis for Omnicell has become more relevant because employee trends can reveal changes in operating scale, cost pressure, and business confidence. Current projections suggest a workforce around about 3,580 employees by April 2026, which should be reviewed alongside revenue and margin trends.
Macro event markers
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes

Management Team Effectiveness

The company has return on total asset (ROA) of 0.36 % which means that it generated a profit of $0.36 on every $100 of assets employed. This is lower than peers in the sector. Similarly, it shows a return on stockholder's equity (ROE) of 0.17 %, which means that it returned $0.17 on every $100 dollars invested by stockholders.
As of 03/23/2026, Common Stock Shares Outstanding is anticipated to decline to approximately 37.5 M. In addition to that, Net Income Applicable To Common Shares is anticipated to decline to approximately 6.2 M.

Stock Institutional Investors

Institutions hold about 98.01% of shares while insiders own roughly 1.99%. Annual revenue is about 1.18 Billion. How the institutional base reacts to earnings changes can move Omnicell in the short term. The business currently sits in the Health Care sector and the Health Care Equipment & Services industry. At that level of institutional ownership, fund flows and rebalancing cycles drive most of the float.
Shares
D. E. Shaw & Co Lp2025-12-31
912 K
Royal Bank Of Canada2025-09-30
668.1 K
Charles Schwab Investment Management Inc2025-12-31
633.1 K
Two Sigma Investments Llc2025-12-31
612.3 K
Mirae Asset Global Etfs Holdings Ltd.2025-12-31
595.7 K
Morgan Stanley - Brokerage Accounts2025-09-30
585.4 K
Federated Hermes Inc2025-09-30
525.4 K
Northern Trust Corp2025-09-30
489.1 K
Boston Partners Global Investors, Inc2025-12-31
447.5 K
Blackrock Inc2025-09-30
7.7 M
Vanguard Group Inc2025-12-31
5.6 M
At 1.5 Billion market cap, Omnicell smaller-cap scale means institutional moves shape liquidity but do not guarantee above-market returns. Annual revenue is about 1.18 Billion. At this size, institutional entries and exits have a more visible impact on daily volume.

Insider Trading Activities

Insider activity around Omnicell matters because officers and directors often act on business changes before the market catches up. Most U.S. insider trades appear in Form 4 filings. The value comes from reading the sequence, not one filing in isolation.

Outstanding Bonds

Outstanding bonds linked to Omnicell can tell investors a great deal about how the company finances itself beyond common equity markets. Used together with earnings and cash-flow analysis, the bond stack can reveal whether leverage is a manageable tool or a developing constraint.

Corporate Filings

F4
17th of March 2026
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
10K
26th of February 2026
Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance
ViewVerify
F4
18th of February 2026
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
5th of February 2026
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
12th of January 2026
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
17th of December 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
8th of December 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
5th of December 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
The majority of Omnicell's outstanding shares are owned by institutions. This level of institutional concentration typically reflects the stock's inclusion in major indices, consistent liquidity, and long-term investment attractiveness for funds managing assets on behalf of pensions, endowments, and other institutional clients. With institutions controlling the majority of the float, changes in quarterly 13F filings can provide meaningful signals about shifts in professional investor sentiment. The ownership breakdown for Omnicell shows approximately 98% institutional, 2% insider, and 0% public.
 
Shares in Circulation  
 First Issued
2001-03-31
 Previous Quarter
46.7 M
 Current Value
45 M
 Average Shares Outstanding
35.3 M
 Quarterly Volatility
M
Macro event markers
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes

Holders Distribution

Institutional ownership analysis for Omnicell matters because banks, hedge funds, pension plans, and other professional investors can influence price and liquidity more forcefully than smaller holders. This matters because getting in early on a sponsorship cycle may help, but getting caught near a large-holder exit can have the opposite effect.

Market Cap and Value

Workforce Comparison

Omnicell carries a third ranking for number of employees within its peer group. The total workforce of Health Care industry is now estimated at about 23,115. Omnicell retains roughly 3,580 in number of employees claiming about 15% of equities under Health Care sector.

Insider Trading History

Omnicell's insider log provides a timeline of management conviction alongside earnings and guidance changes. Current market capitalization is about 1.5 Billion. Larger blocks and clustered timing carry more weight than isolated trades.
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2026-03-01
0.3
3
10
139,348
54,391
2025-12-01
0.1818
2
11
61,182
90,420
2025-09-01
0.2
1
5
7,663
19,323
2025-06-01
1.3333
8
6
54,315
16,560
2025-03-01
0.7
7
10
461,604
42,069
2024-12-01
0.1667
1
6
53,520
18,397
2024-09-01
0.25
1
4
6,647
10,298
2024-06-01
3.0
9
3
52,057
2,937
2024-03-01
1.6667
5
3
179,546
277.00
2023-09-01
1.3333
4
3
6,132
488.00
2023-06-01
1.8571
13
7
123,131
18,707
2023-03-01
0.1667
1
6
19,329
32,695
2022-12-01
0.3158
6
19
15,778
43,818
2022-09-01
0.2727
3
11
26,500
78,410
2022-06-01
1.0
10
10
19,789
25,916
2022-03-01
1.5
15
10
216,391
18,243
2021-12-01
0.1111
4
36
60,034
154,205
2021-09-01
0.1905
8
42
92,992
213,812
2021-06-01
1.0
9
9
10,363
19,677
2021-03-01
1.6667
10
6
108,072
7,655
2020-12-01
0.2083
5
24
57,500
146,940
2020-09-01
0.1429
1
7
6,301
24,973
2020-06-01
0.625
10
16
28,549
37,088
2020-03-01
0.6667
16
24
278,892
112,918
2019-12-01
0.2667
8
30
68,067
154,905
2019-09-01
0.25
2
8
7,550
21,602
2019-06-01
0.3889
21
54
136,886
234,738
2019-03-01
0.46
23
50
413,679
253,760
2018-12-01
0.125
4
32
21,474
80,650
2018-09-01
0.1563
5
32
30,840
108,792
2018-06-01
0.5
20
40
201,986
243,127
2018-03-01
1.4
21
15
554,943
38,775
2017-12-01
0.4615
12
26
80,822
128,208
2017-09-01
1.5333
23
15
302,410
180,562
2017-06-01
1.25
30
24
185,929
160,791
2017-03-01
2.5556
23
9
480,996
18,360
2016-12-01
0.7273
8
11
51,296
61,924
2016-09-01
1.3333
24
18
107,836
106,495
2016-06-01
2.2353
38
17
198,915
116,572
2016-03-01
2.3571
33
14
469,575
77,158
2015-12-01
0.5882
10
17
111,964
90,083
2015-09-01
1.6429
23
14
227,898
80,069
2015-06-01
1.0357
29
28
97,382
108,464
2015-03-01
1.3684
26
19
250,550
67,332
2014-12-01
0.9444
34
36
175,467
161,131
2014-09-01
0.6667
18
27
215,750
139,384
2014-06-01
0.9048
38
42
180,031
233,406
2014-03-01
0.9286
52
56
588,043
430,419
2013-12-01
0.4915
29
59
190,763
275,713
2013-09-01
0.411
30
73
340,424
532,468
2013-06-01
0.6667
40
60
312,844
450,521
2013-03-01
0.7294
62
85
635,260
545,565
2012-12-01
0.2973
11
37
188,441
371,210
2012-09-01
0.6111
11
18
141,093
127,658
2012-06-01
1.6667
35
21
211,724
98,361
2012-03-01
0.9167
44
48
404,104
213,163
2011-12-01
0.439
18
41
27,891
128,289
2011-09-01
0.4074
22
54
51,366
117,119
2011-06-01
0.7451
38
51
103,694
124,898
2011-03-01
1.44
36
25
369,526
55,973
2010-12-01
0.3784
14
37
26,944
59,017
2010-09-01
0.5714
12
21
50,025
83,137
2010-06-01
1.1071
31
28
113,368
67,909
2010-03-01
0.8929
25
28
441,087
273,768
2009-12-01
0.25
2
8
158,606
316,867
2009-09-01
0.2
6
30
60,000
272,812
2009-06-01
6.25
25
4
174,527
8,287
2009-03-01
1.8571
13
7
429,688
3,992
2008-12-01
0.3333
2
6
68,000
25,460
2008-09-01
0.625
30
48
64,200
360,443
2008-06-01
5.2
26
5
130,173
7,541
2008-03-01
0.8219
60
73
370,429
262,438
2007-12-01
0.5
47
94
119,294
476,777
2007-09-01
0.5619
59
105
285,558
629,283
2007-06-01
1.5455
34
22
152,457
116,004
2007-03-01
1.7188
110
64
1,252,422
479,396
2006-12-01
2.3333
56
24
390,652
666,720
2006-09-01
0.875
14
16
156,562
240,027
2006-06-01
3.0
12
4
178,216
29,582
2006-03-01
0.6429
18
28
431,041
446,982
2005-12-01
0.6667
8
12
324,000
49,529
2005-09-01
0.5
2
4
29,000
43,625
2005-06-01
2.0
8
4
50,000
237,500
2005-03-01
2.0
8
4
227,250
60,625
2004-12-01
1.6923
22
13
1,097,741
170,113
2004-09-01
0.4286
6
14
36,750
133,500
2004-06-01
1.0
14
14
92,850
94,450
2004-03-01
0.6111
33
54
268,932
12,084,248
2003-12-01
0.6
21
35
438,812
4,908,275
2003-09-01
0.5333
8
15
153,650
233,792
2003-06-01
1.4
7
5
43,750
102,500

Notable Stakeholders

Reviewing the stakeholders around Omnicell can help investors understand which people or institutions may influence direction, governance, and strategic pressure. The practical value is that investors can see where interests align, where they conflict, and how that tension could influence execution.
Randall LippsExecutive Chairman, CEO and PresProfile
Jorge TaborgaExecutive Vice President - EngineeringProfile
Scott SeidelmannExecutive Vice President and Chief Commercial OfficerProfile
Peter KuipersCFO, Executive Vice PresidentProfile
Nchacha EttaExecutive CFOProfile
Baird IIIExecutive CFOProfile
Nnamdi NjokuExecutive COOProfile
Perry GenovaSenior CTOProfile
Corey JDChief VPProfile
Dave FordSVP OfficerProfile
Brian NuttChief VPProfile
Joseph SpearsPrincipal Chief Accounting OfficerProfile
Kathleen NemethSenior RelationsProfile
Tomer StavitskySenior OfficerProfile
Stella PrefachSenior OfficerProfile
Vicki MacDevittChief StaffProfile
Sara DalmassoSenior InternationalProfile
Minoo MortazaviSenior OperationsProfile
Corey ManleyExecutive OfficerProfile
David VanellaSenior RegulatoryProfile
Roxanne TurnerSr OfficerProfile
Christine MellonChief VPProfile
Maximo RochaSenior OfficerProfile
Giri ChodavarapuSenior OfficerProfile

Management Information & Data Sources

Omnicell is a small-cap company in Health Care Technology, Health Care Equipment & Services, Health Care. Executive review focuses on insiders, senior management, and employee signals. Leadership stability matters when evaluating execution against stated business priorities. CEO is Randall Lipps with 3,580 employees and 24 reported executives.

For Omnicell, this section uses periodic company reporting and market reference feeds with Macroaxis normalization rules applied to keep cross-asset comparisons consistent. Analyst inputs may be included when coverage is available. Intraday timing differences may exist. Insider and management fields are mapped from published filings and company disclosures.

This content is curated and reviewed by:

Gabriel Shpitalnik - Member of Macroaxis Editorial Board
Last reviewed on March 1st, 2026

Workforce Efficiency and Productivity

Workforce metrics tied to Omnicell offer a useful way to test whether headcount and economic output are moving in a productive direction. This is most informative when investors want to connect operating scale with efficiency rather than reviewing headcount in isolation.

Omnicell Manpower Efficiency

Return on Omnicell Manpower

Revenue Per Employee331K
Revenue Per Executive49.4M
Net Income Per Employee573
Net Income Per Executive85.5K
Working Capital Per Employee56.8K
Working Capital Per Executive8.5M

More Resources for Omnicell Stock Analysis

A clear view of Omnicell comes from reviewing its financial structure and trends. The information reflects Omnicell's most recent reporting inputs.